In vivo evidence for protease-catalysed mechanism providing bioactive tumor necrosis factor alpha

Biochem Pharmacol. 1990 Oct 1;40(7):1601-3. doi: 10.1016/0006-2952(90)90461-s.

Abstract

Mice pretreated by intravenous injection of 42 mg/kg of the serine protease inhibitor alpha 1-antitrypsin prior to a hepatotoxic dose of D-galactosamine/lipopolysaccharide (GalN/LPS) were fully protected against hepatitis. Pretreatment with alpha 1-antitrypsin with doses up to 300 mg/kg at different times failed to protect galactosamine sensitized animals against tumor necrosis factor alpha (TNF alpha)-induced hepatitis. No bioactive TNF alpha was detectable in serum of mice protected against GalN/LPS-induced hepatitis by pretreatment with alpha 1-antitrypsin. In contrast, abundant amounts of TNF were found in sera of GalN/LPS-treated control animals. It is concluded that a serine protease sensitive to alpha 1-antitrypsin provides bioactive TNF alpha by proteolytic cleavage of a TNF alpha precursor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Galactosamine / toxicity
  • Hepatitis, Animal / chemically induced
  • Hepatitis, Animal / prevention & control
  • Lipopolysaccharides / toxicity
  • Male
  • Mice
  • Models, Biological
  • Serine Endopeptidases / metabolism*
  • Serine Proteinase Inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Tumor Necrosis Factor-alpha / toxicity
  • alpha 1-Antitrypsin / pharmacology

Substances

  • Lipopolysaccharides
  • Serine Proteinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • alpha 1-Antitrypsin
  • Galactosamine
  • Alanine Transaminase
  • Serine Endopeptidases